Notify me when ACUTA CAPITAL PARTNERS, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 30 | $147,286,583 | +$27,001,290 | -$35,460,486 | -$8,459,196 | TERN, PRAX, CDTX, OCUL, WHWK | 13F-HR | 17 Feb 2026, 12:03 |
| Q3 2025 | 28 | $96,768,753 | +$18,369,713 | -$24,314,430 | -$5,944,717 | OCUL, CDTX, TRML, WHWK, INSM | 13F-HR | 14 Nov 2025, 15:08 |
| Q2 2025 | 28 | $71,638,466 | +$8,123,297 | -$30,810,273 | -$22,686,976 | OCUL, CDTX, WHWK, SLNO, TRML | 13F-HR | 14 Aug 2025, 16:50 |
| Q1 2025 | 33 | $86,228,809 | +$21,196,096 | -$22,394,102 | -$1,198,006 | OCUL, INSM, TRML, WHWK, ELVN | 13F-HR | 15 May 2025, 06:33 |
| Q4 2024 | 39 | $99,403,764 | +$15,962,211 | -$31,533,383 | -$15,571,172 | OCUL, INSM, TRML, CRNX, ELVN | 13F-HR | 14 Feb 2025, 07:05 |
| Q3 2024 | 41 | $123,463,831 | +$31,090,399 | -$45,501,795 | -$14,411,396 | PCVX, OCUL, TRML, INSM, ELVN | 13F-HR | 14 Nov 2024, 07:06 |
| Q2 2024 | 32 | $118,636,478 | +$19,115,318 | -$39,582,265 | -$20,466,947 | OCUL, ELVN, PCVX, DYN, PRAX | 13F-HR | 14 Aug 2024, 09:16 |
| Q1 2024 | 33 | $153,941,445 | +$30,200,665 | -$93,694,806 | -$63,494,141 | OCUL, PRAX, MRSN, TSHA, RCKT | 13F-HR | 15 May 2024, 07:56 |
| Q4 2023 | 38 | $177,629,622 | +$56,683,546 | -$50,750,850 | +$5,932,696 | RYZB, CBAY, RCKT, KURA, EYPT | 13F-HR | 14 Feb 2024, 10:29 |
| Q3 2023 | 42 | $137,518,337 | +$42,104,307 | -$27,896,018 | +$14,208,289 | TSHA, APLS, AADI, PRAX, RYZB | 13F-HR | 14 Nov 2023, 09:16 |
| Q2 2023 | 35 | $147,604,554 | +$39,337,743 | -$33,676,837 | +$5,660,906 | APLS, AADI, TERN, KURA, SNDX | 13F-HR | 14 Aug 2023, 07:49 |
| Q1 2023 | 33 | $128,494,226 | +$12,371,588 | -$34,630,389 | -$22,258,801 | APLS, AADI, TERN, CBAY, VTYX | 13F-HR | 15 May 2023, 07:26 |
| Q4 2022 | 34 | $154,942,944 | +$42,595,173 | -$100,092,853 | -$57,497,680 | AADI, VRDN, APLS, TERN, UTHR | 13F-HR | 14 Feb 2023, 16:08 |
| Q3 2022 | 46 | $224,818,000 | +$48,195,153 | -$35,648,886 | +$12,546,267 | APLS, AADI, BLU, RLMD, ISEE | 13F-HR | 14 Nov 2022, 10:24 |
| Q2 2022 | 41 | $178,805,000 | +$30,901,863 | -$24,850,765 | +$6,051,098 | APLS, AADI, VTGN, KURA, BLSA | 13F-HR | 15 Aug 2022, 18:10 |
| Q1 2022 | 38 | $210,127,000 | +$34,945,352 | -$30,062,239 | +$4,883,113 | APLS, AADI, VTGN, CLDX, RLMD | 13F-HR | 16 May 2022, 08:37 |
| Q4 2021 | 36 | $237,734,000 | +$64,199,755 | -$87,675,217 | -$23,475,462 | AADI, APLS, VTGN, CLDX, GHRS | 13F-HR | 14 Feb 2022, 08:12 |
| Q3 2021 | 46 | $280,970,000 | +$100,247,108 | -$79,444,110 | +$20,802,998 | AADI, VTGN, ISEE, CLDX, BLU | 13F-HR | 15 Nov 2021, 14:24 |
| Q2 2021 | 37 | $233,521,000 | +$29,674,035 | -$85,553,033 | -$55,878,998 | VTGN, CLDX, APLS, ARWR, BLSA | 13F-HR | 16 Aug 2021, 12:05 |
| Q1 2021 | 46 | $277,340,000 | +$82,414,295 | -$139,195,850 | -$56,781,555 | VTGN, CLDX, KURA, AVDL, ISEE | 13F-HR | 17 May 2021, 11:27 |
| Q4 2020 | 50 | $363,194,000 | +$93,251,868 | -$126,452,733 | -$33,200,865 | CLDX, SAGE, KURA, LRMR, MRSN | 13F-HR | 16 Feb 2021, 06:04 |
| Q3 2020 | 42 | $340,366,000 | +$129,583,396 | -$173,565,838 | -$43,982,442 | IMMU, KURA, CLDX, SAGE, CMPS | 13F-HR | 16 Nov 2020, 12:17 |
| Q2 2020 | 46 | $346,112,000 | +$150,669,012 | -$75,552,384 | +$75,116,628 | ADVM, IMMU, BTAI, IOVA, MRSN | 13F-HR | 14 Aug 2020, 16:22 |
| Q1 2020 | 32 | $206,318,000 | +$61,827,443 | -$138,516,511 | -$76,689,068 | AVDL, AXSM, ADVM, IOVA, ARVN | 13F-HR | 15 May 2020, 16:11 |
| Q4 2019 | 35 | $351,657,000 | +$151,840,079 | -$42,453,035 | +$109,387,044 | AXSM, ARWR, KDMN, AUPH, ITCI | 13F-HR | 14 Feb 2020, 10:50 |
| Q3 2019 | 30 | $127,106,000 | +$24,863,572 | -$121,137,606 | -$96,274,034 | KDMN, IOVA, ARVN, ARWR, AXSM | 13F-HR | 13 Nov 2019, 21:15 |
| Q2 2019 | 27 | $259,307,000 | +$81,978,073 | -$73,019,450 | +$8,958,623 | IOVA, KDMN, ADVM, VCYT, ARWR | 13F-HR | 14 Aug 2019, 15:36 |
| Q1 2019 | 31 | $207,597,000 | +$74,950,646 | -$11,437,877 | +$63,512,769 | IOVA, KDMN, ASMB, CASM, INSM | 13F-HR | 13 May 2019, 21:46 |
| Q4 2018 | 18 | $116,243,000 | +$16,893,050 | -$91,303,318 | -$74,410,268 | IOVA, ASMB, KDMN, CASM, BHVN | 13F-HR | 14 Feb 2019, 10:22 |
| Q3 2018 | 23 | $249,568,000 | +$6,207,256 | -$243,712,987 | -$237,505,731 | IMMU, ASMB, IOVA, KDMN, CEMI | 13F-HR | 06 Nov 2018, 21:11 |
| Q2 2018 | 37 | $506,858,000 | +$96,909,665 | -$105,463,347 | -$8,553,682 | IMMU, IOVA, ASMB, ARGX, KDMN | 13F-HR | 14 Aug 2018, 21:12 |
| Q1 2018 | 30 | $477,267,000 | +$82,154,183 | -$58,550,122 | +$23,604,061 | IMMU, IOVA, ASMB, ASND, ARGX | 13F-HR | 15 May 2018, 06:13 |
| Q4 2017 | 31 | $402,968,000 | +$52,922,789 | -$38,075,746 | +$14,847,043 | IMMU, ASMB, IOVA, VCYT, ASND | 13F-HR | 13 Feb 2018, 21:24 |
| Q3 2017 | 35 | $370,868,000 | +$149,766,520 | -$57,973,355 | +$91,793,165 | IMMU, ASMB, VCYT, IOVA, INTEC PHARMA LTD JERUSALEM | 13F-HR | 14 Nov 2017, 16:40 |
| Q2 2017 | 35 | $244,962,000 | +$86,187,972 | -$103,877,615 | -$17,689,643 | ASND, VCYT, IOVA, ASMB, IRIX | 13F-HR | 11 Aug 2017, 18:07 |
| Q1 2017 | 41 | $276,509,000 | +$73,902,453 | -$95,853,003 | -$21,950,550 | VCYT, ASMB, LBIO, IRIX, ACAD | 13F-HR | 15 May 2017, 06:20 |
| Q4 2016 | 38 | $250,830,000 | +$71,380,933 | -$64,144,790 | +$7,236,143 | VCYT, LBIO, IRIX, IMMU, NEURODERM LTD | 13F-HR | 13 Feb 2017, 16:26 |
| Q3 2016 | 53 | $243,450,000 | +$66,342,715 | -$55,476,069 | +$10,866,646 | LBIO, VCYT, IRIX, IMMU, EVDY | 13F-HR | 15 Nov 2016, 06:04 |
| Q2 2016 | 56 | $198,606,000 | +$69,496,184 | -$45,595,943 | +$23,900,241 | LBIO, VCYT, IRIX, NEURODERM LTD, IMMU | 13F-HR | 15 Aug 2016, 14:09 |
| Q1 2016 | 36 | $172,667,000 | +$64,427,447 | -$52,000,594 | +$12,426,853 | FOLD, VCYT, IMMU, LBIO, NEURODERM LTD | 13F-HR | 13 May 2016, 17:05 |
| Q4 2015 | 47 | $187,688,000 | +$85,263,067 | -$53,215,921 | +$32,047,146 | OLED, LBIO, FOLD, VCYT, IMMU | 13F-HR | 12 Feb 2016, 16:53 |
| Q3 2015 | 52 | $157,605,000 | +$65,635,530 | -$39,159,729 | +$26,475,801 | FOLD, EXEL, NEURODERM LTD, ASND, LBIO | 13F-HR | 16 Nov 2015, 16:43 |
| Q2 2015 | 49 | $152,800,000 | +$75,109,798 | -$37,124,603 | +$37,985,195 | FOLD, AGTC, VCYT, LBIO, ASND | 13F-HR | 14 Aug 2015, 06:08 |
| Q1 2015 | 46 | $111,567,000 | +$46,481,853 | -$44,609,110 | +$1,872,743 | FOLD, LBIO, CEMP, ALIM, BEAT | 13F-HR | 14 May 2015, 17:49 |
| Q4 2014 | 54 | $101,310,000 | $0 | $0 | $0 | FOLD, ALIM, PTX, BEAT, EXELIXIS INC | 13F-HR | 12 Feb 2015, 17:54 |